Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA4 | P22748 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CMA1 | P23946 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.34 |
| ▸ | S100A4 | P26447 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7572657 | 0.76 | CA1 (0.40) | CA1CA2CA4CA7CA9 | |
| SCHEMBL2074190 | 0.72 | ALDH1A1 (0.49) | CA1CA2CA4CA7CA9 | |
| SCHEMBL302509 | 0.70 | MAOA (0.37) | CA1CA2CA4CA7CA9 | |
| SCHEMBL8078367 | 0.66 | S100A4 (0.44) | TGM2CES1CA1CA2CA4 | |
| SCHEMBL28881913 | 0.65 | TGM2 (0.71) | TGM2CES1CA1CA2CA4 | |
| SCHEMBL11920848 | 0.65 | TGM2 (0.71) | TGM2CES1CA1CA2CA4 | |
| SCHEMBL1943737 | 0.64 | CA1 (0.36) | TGM2CA1CA2CA4CA7 | |
| SCHEMBL30972546 | 0.64 | TGM2 (0.77) | TGM2CES1MEN1KMT2AHSP90AA1 | |
| SCHEMBL31223925 | 0.63 | TGM2 (0.46) | TGM2CES1CA1CA2CA4 | |
| SCHEMBL31344378 | 0.63 | TGM2 (0.46) | TGM2CES1CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023104170-A1 | COMPOUNDS FOR TREATING POLYQ-RELATED NEURODEGENERATIVE DISORDERS | HANGZHOU JIJING PHARMACEUTICAL TECHNOLOGY LIMITED (CN) | 2023-06-15 | — | — | WO | disclosed |
| EP-1951215-A4 | HYDRAZONE DERIVATIVES AND USES THEREOF | REDPOINT BIO CORP (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-1951215-A2 | HYDRAZONE DERIVATIVES AND USES THEREOF | Redpoint Bio Corporation (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20070207093-A1 | Hydrazone derivatives and uses thereof | LINQUAGEN CORP. | 2007-09-06 | — | — | US | disclosed |
| WO-2007056159-A2 | HYDRAZONE DERIVATIVES AND USES THEREOF | REDPOINT BIO CORPORATION (US) | 2007-05-18 | — | — | WO | disclosed |
| US-7205328-B2 | Aids viricide | IRM LLC (BM) | 2007-04-17 | — | — | US | disclosed |
| US-20040152755-A1 | Oxindoles with anti-HIV activity | IRM LLC, A DELAWARE LLC (BM) | 2004-08-05 | — | — | US | disclosed |
| WO-2004037247-A1 | OXINDOLES WITH ANTI-HIV ACTIVITY | IRM LLC (BM) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207093-A1 | Hydrazone derivatives and uses thereof | TAS2R1, TAS2R5, TAS1R1 | TGM2 2792/4885CES1 2928/4885CA1 214/4885 |
| US-20040152755-A1 | Oxindoles with anti-HIV activity | IDO1, API5, NFATC1 | TGM2 4594/4885CES1 3031/4885CA1 4412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.